Journal article
36 International neoadjuvant kidney cancer consortium guidelines on assessing pathological response after neoadjuvant therapy in kidney cancer
- Abstract:
-
Background: Despite effective surgery and adjuvant immunotherapy, 1/3 of patients with initially localised renal cell carcinoma (RCC) will go on to develop relapse. Neoadjuvant therapy might improve outcomes for some of these patients; however, the approach has not been widely adopted due to a lack of prospective randomised trial data. Designing prospective neoadjuvant studies for RCC depends on properly defined clinicopathological endpoints. Pathological response is a surrogate marker of eff...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 261.6KB, Terms of use)
-
- Publisher copy:
- 10.1093/oncolo/oyaf276.037
Authors
- Publisher:
- Oxford University Press
- Journal:
- The Oncologist More from this journal
- Volume:
- 30
- Issue:
- Supplement_2
- Article number:
- oyaf276.037
- Publication date:
- 2025-10-09
- DOI:
- EISSN:
-
1549-490X
- ISSN:
-
1083-7159
- Language:
-
English
- Keywords:
- Pubs id:
-
2301597
- Local pid:
-
pubs:2301597
- Source identifiers:
-
3358179
- Deposit date:
-
2025-10-09
- ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.
Terms of use
- Copyright date:
- 2025
If you are the owner of this record, you can report an update to it here: Report update to this record